-
Professor Bing Han: Treatment Strategies for Aplastic Anemia in the TPO-RA Era
Editor’s Note: The 13th Ludaopei Hematology Academic Conference, jointly organized by the Beijing Health Promotion Association and the Hongmian Tumor and Rare Disease Public Welfare Foundation, and hosted by the…
-
Professor Robert Negrin, ASH President-Elect: Immunoregulatory Mechanisms to Improve Transplant Outcomes
Editor’s Note: The 13th Ludaopei Hematology Academic Conference, jointly organized by the Beijing Health Promotion Association and the Guangzhou Hongmian Tumor and Rare Disease Public Welfare Foundation and hosted by…
-
Professor Jinchun Xing: Advances and Future Perspectives in the Diagnosis and Treatment of Urothelial Carcinoma | 2025 Pujiang Uro-Oncology Conference
Urothelial carcinoma (UC) is a highly aggressive malignancy with high incidence and severe complications, significantly impacting patients’ quality of life and survival outcomes. In recent years, there have been remarkable advances in both the diagnosis and treatment of UC. At the 2025 Pujiang Uro-Oncology Conference—jointly organized by the CSCO Urothelial Carcinoma Expert Committee, CSCO Renal…
-
Professor Zhuowei Liu: Pioneering a New Paradigm in Urothelial Carcinoma Treatment – From Surgical Innovations to Mechanistic Insights | 2025 Pujiang Uro-Oncology Conference
At the recently concluded 2025 Pujiang Uro-Oncology Conference, the “High-Quality Development Forum on Urologic Oncology” drew considerable attention as leading domestic and international experts shared cutting-edge clinical and translational research progress. Professor Zhuowei Liu from Sun Yat-sen University Cancer Center (SYSUCC) was invited to present his team’s series of innovative studies in the field of…
-
Professor Qing Zou: Advancing Comprehensive Therapy and “Full-Course Management” Systems for Urologic Malignancies
In recent years, the management of urologic malignancies—including kidney cancer and bladder cancer—has been moving toward a new era of comprehensive care, innovative treatments, multidisciplinary collaboration (MDT), and multi-technology integration. The goal is to build a “full-course management” system that maximizes clinical benefit for patients by combining advances from across specialties. At the 2025 Pujiang…
-
Professor Yue Lu: Second Allogeneic Hematopoietic Stem Cell Transplantation for Post-Transplant Relapse in Acute Leukemia
Editor’s Note: On August 22–23, 2025, the 13th Lu Daopei Hematology Conference was successfully held in Beijing, jointly organized by the Beijing Health Promotion Association and the Guangzhou Kapok Oncology…
-
Professor Francesca Lorraine Wei Inng Lim: The Cell Therapy Landscape in Singapore
On August 22–23, 2025, the 13th Lu Daopei Hematology Conference was held in Beijing, jointly organized by the Beijing Health Promotion Association and the Guangzhou Kapok Oncology & Rare Disease…
Connecting Medical Expertise through Media